Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications.
- 1Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
- 2Department of Medical Biosciences, Umeå University, Umeå, Sweden.
Abstract
Background
Routine targeted genomic profiling in non-small cell lung cancer (NSCLC) is primarily used to identify actionable alterations but may provide more information for clinical decision making. In this study routine genomic profiling data were used to examine the mutational landscape of lung cancer and its relationship to patient characteristics.Materials and methods
We analyzed Archer VariantPlex 67-gene sequencing data from 528 patients diagnosed with lung cancer in the North Swedish Health Care Region between 2011 and 2021 and linked the genomic results to registry-derived clinical and demographic data. Mutation frequencies, positional architectures, subgroup enrichments, and survival associations were compared within the regional cohort and against an external reference cohort assembled from cBioPortal.Results
After quality filtering, 1,415 somatic variants across 60 genes were identified, with a mean of 2.68 mutations per tumor, indicating substantial heterogeneity in mutational profiles. TP53 and KRAS formed a conserved mutational backbone across cohorts, whereas EGFR was less frequent and MET, APC, ATM, and CDKN2A were enriched in North Sweden relative to the external reference cohort. Major hotspot architectures were broadly preserved, although MET showed the clearest positional divergence. Mutation patterns varied by age, sex, smoking status, and disease stage. EGFR defined the most coherent clinical subtype, being enriched in females, never-smokers, younger patients, and earlier-stage disease, whereas KRAS, STK11, and TP53 were associated with smoking. EGFR was the strongest favorable prognostic marker, but stage strongly influenced the interpretation of many survival differences, indicating that gene-level prognostic signals are closely shaped by clinical context.Conclusions
Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context. These findings support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
Related
- Genomic analysis and antimicrobial resistance profiling of Klebsiella pneumoniae clinical isolates from urinary tract infections in India: prevalence of class A β-lactamase with molecular docking and simulation insights.
- Genomic foundation model-derived disruption profiling links somatic mutations to cancer biology and clinical outcomes
- Rebound pain after regional anesthesia in orthopedic surgery: current evidence and clinical implications – a narrative review
- Same zone diameter, different verdict: clinical and surveillance implications of EUCAST 2025 versus CLSI 2025 breakpoint discordance among Enterobacterales, Staphylococcus and Pseudomonas isolates at Buea Regional Hospital, Cameroon
- National trends, incidence and regional variations in lower extremity amputations in Sweden, 2008–2024: a register-based study
BibTeX
@article{karlowatz2026real,
title = {{Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications.}},
author = {Nicholas Karlowatz and Linda Köhn and Cedric Patthey and Jonas Nilsson and Mikael B Johansson},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1882423},
url = {https://europepmc.org/article/MED/42839920},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications.
AU - Nicholas Karlowatz
AU - Linda Köhn
AU - Cedric Patthey
AU - Jonas Nilsson
AU - Mikael B Johansson
PY - 2026
DA - 2026/09/22
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1882423
UR - https://europepmc.org/article/MED/42839920
AB - Background Routine targeted genomic profiling in non-small cell lung cancer (NSCLC) is primarily used to identify actionable alterations but may provide more information for clinical decision making. In this study routine genomic profiling data were used to examine the mutational landscape of lung cancer and its relationship to patient characteristics.Materials and methods We analyzed Archer VariantPlex 67-gene sequencing data from 528 patients diagnosed with lung cancer in the North Swedish Health Care Region between 2011 and 2021 and linked the genomic results to registry-derived clinical and demographic data. Mutation frequencies, positional architectures, subgroup enrichments, and survival associations were compared within the regional cohort and against an external reference cohort assembled from cBioPortal.Results After quality filtering, 1,415 somatic variants across 60 genes were identified, with a mean of 2.68 mutations per tumor, indicating substantial heterogeneity in mutational profiles. TP53 and KRAS formed a conserved mutational backbone across cohorts, whereas EGFR was less frequent and MET, APC, ATM, and CDKN2A were enriched in North Sweden relative to the external reference cohort. Major hotspot architectures were broadly preserved, although MET showed the clearest positional divergence. Mutation patterns varied by age, sex, smoking status, and disease stage. EGFR defined the most coherent clinical subtype, being enriched in females, never-smokers, younger patients, and earlier-stage disease, whereas KRAS, STK11, and TP53 were associated with smoking. EGFR was the strongest favorable prognostic marker, but stage strongly influenced the interpretation of many survival differences, indicating that gene-level prognostic signals are closely shaped by clinical context.Conclusions Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context. These findings support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
SN - 2234-943X
ER -